INSIGHTS ON CLINICAL TRIAL DESIGN

  • The Latest Generation Of Patient Recruitment Has Arrived
    10/29/2025

    In the final session of our three-part webinar series, we explore what this next phase of evolution means for clinical trial planning and execution, and examine how innovative approaches are reshaping recruitment strategies from the ground up.

  • Where Study Simulation Fits In Clinical Trials
    4/21/2026

    Simulation lets teams test assumptions early, showing how design and operations affect timelines, cost, and feasibility — reducing risk and enabling confident, data‑driven decisions.

  • Outlook Good For 7 Drugs Up For Q3 Review
    8/15/2024

    A total of 24 drugs, devices, diagnostics, and deals are expected to progress in the third quarter of 2024, including approval applications for 17 drugs. The estimated overall likelihood of approval is 90% or higher for seven of those drugs, including revumenib for acute myelogenous leukemia and KarXT for schizophrenia.

  • How State-Of-The-Art Clinical Trial Mobile Vision Clinics Work
    3/11/2025

    Are you seeking a non-traditional option to complete the eye exams necessary for your ocular clinical trials? A mobile clinic may be the solution you're looking for.

  • Five Predictions For Clinical Research In 2025
    2/19/2025

    In 2025, AI-powered adaptive protocols will redefine study design, shifting the industry from rigid, pre-planned models to flexible, real-world-optimized trials.

CLINICAL TRIAL DESIGN SOLUTIONS

  • AutoCruitment's patient recruitment services have assisted with 700+ trials in more than 38 countries. Looking for patients with over 120 different conditions, they have enrolled 14600+ patients and achieved a 97% increase in randomization.

  • From our inception, Ergomed has been committed to enhancing the patient journey in clinical trials. Our unique Ergomed CARE™ approach revolutionizes trials by optimizing the patient experience. Designed to address and resolve issues proactively, this comprehensive approach supports and engages all stakeholders, leading to accelerated study start-up, improved patient recruitment and retention, and investigator engagement.

  • Learn about a unified ecosystem integrating eConsent, IRT, eCOA, and ePatient into a seamless workstream designed with a patient-centric approach.

  • The Australian Advantage is about saving time and minimizing costs while generating internationally accepted data in preparation for the next Phase.

  • Flow cytometry is a foundational tool in modern drug development, and its application in receptor occupancy assays has become essential for evaluating therapeutic engagement with disease targets.